Antiphospholipid antibodies in critically ill patients

Antiphospholipid antibodies are responsible for a wide spectrum of clinical manifestations. Venous, arterial and microvascular thrombosis and severe catastrophic cases account for a large morbidly/mortality. Through the connection between the immune, inflammatory and hemostatic systems, it is possible that these antibodies may contribute to the development of organ dysfunction and are associated with poor short and long-term prognoses in critically ill patients. We performed a search of the PubMed/MedLine database for articles written during the period from January 2000 to February 2013 to evaluate the frequency of antiphospholipid antibodies in critically ill patients and their impact on the outcomes of these patients. Only eight original studies involving critically ill patients were found. However, the development of antiphospholipid antibodies in critically ill patients seems to be frequent, but more studies are necessary to clarify their pathogenic role and implications for clinical practice.

[1]  M. Wislowska.  [Catastrophic antiphospholipid syndrome]. , 2015, Wiadomosci lekarskie.

[2]  M. Soares,et al.  Antiphospholipid antibodies in critically ill patients with cancer: a prospective cohort study. , 2014, Journal of critical care.

[3]  Hong Zhou,et al.  Anti-β2GPI/β2GPI stimulates activation of THP-1 cells through TLR4/MD-2/MyD88 and NF-κB signaling pathways. , 2013, Thrombosis research.

[4]  M. Rybojad,et al.  Prognostic contributions of the underlying inflammatory disease and acute organ dysfunction in critically ill patients with systemic rheumatic diseases. , 2013, European journal of internal medicine.

[5]  S. Krilis,et al.  The pathogenesis of the antiphospholipid syndrome. , 2013, The New England journal of medicine.

[6]  R. Cervera.  CAPS Registry , 2012, Lupus.

[7]  R. Derksen,et al.  Pathophysiology of thrombotic APS: where do we stand? , 2012, Lupus.

[8]  G. Espinosa,et al.  Mortality and long term survival prognostic factors of patients with systemic autoimmune diseases admitted to an intensive care unit: a retrospective study. , 2012, Clinical and experimental rheumatology.

[9]  G. Espinosa,et al.  Update on the Catastrophic Antiphospholipid Syndrome and the “CAPS Registry” , 2012, Seminars in Thrombosis & Hemostasis.

[10]  K. McCrae,et al.  A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. , 2012, Blood.

[11]  W. Ruf,et al.  Tissue factor and cell signalling in cancer progression and thrombosis , 2011, Journal of thrombosis and haemostasis : JTH.

[12]  E. Kruithof,et al.  Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies. , 2011, Blood.

[13]  Y. Shoenfeld,et al.  Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". , 2009, Journal of autoimmunity.

[14]  M. Soares,et al.  Antiphospholipid Antibodies and Multiple Organ Failure in Critically Ill Cancer Patients , 2009, Clinics.

[15]  M. Hollenberg,et al.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more , 2008, British journal of pharmacology.

[16]  R. Asherson.  The catastrophic antiphospholipid (Asherson's) syndrome. , 2008, Autoimmunity reviews.

[17]  G. Espinosa,et al.  Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. , 2006, Autoimmunity reviews.

[18]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[19]  R. Jaeschke,et al.  The incidence and impact of lupus anticoagulants among patients in the intensive care unit. , 2005, Saudi medical journal.

[20]  G. Nakos,et al.  Anti-phospholipid antibodies in serum from patients with Guillain-Barré syndrome , 2005, Intensive Care Medicine.

[21]  G. Espinosa,et al.  Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients , 2005, Annals of the rheumatic diseases.

[22]  B. Hammond.  Lupus , 2004 .

[23]  G. Espinosa,et al.  The Catastrophic Antiphospholipid Syndrome , 2014, Current rheumatology reports.

[24]  Y. Shoenfeld,et al.  Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines , 2003, Lupus.

[25]  W. Schobersberger,et al.  Prospective observational study of antiphospholipid antibodies in acute lung injury and acute respiratory distress syndrome: comparison with catastrophic antiphospholipid syndrome , 2003, Lupus.

[26]  S. Chinn,et al.  Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome , 2002, Annals of the rheumatic diseases.

[27]  K. Laczika,et al.  Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions , 2002, Critical care medicine.

[28]  G. Nakos,et al.  Autoantibodies to lipids in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome , 2001, Critical care medicine.

[29]  J. Marshall,et al.  Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome , 2001, Critical care medicine.

[30]  C. Kitchens,et al.  Thrombotic storm: when thrombosis begets thrombosis. , 1998, The American journal of medicine.

[31]  E. Harris,et al.  The antiphospholipid syndrome , 1995, Clinical reviews in allergy & immunology.